SENP6-GPR124 Fusion FISH Probe
The SENP6-GPR124 Fusion FISH Probe is used to confirm a fusion of the SENP6 and GPR124 genes. The fusion of the SENP6 and GPR124 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| SENP6-GPR124-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-RERE | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-REOR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-REGO | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-REGR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-OROR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GORE | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GROR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| SENP6-GPR124-20-AQAQ | 20 (40 μL) | 200 μL |
|
SENP6 Gene Summary
Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]). SENPs also display isopeptidase activity for deconjugation of SUMO-conjugated substrates (Lima and Reverter, 2008 [PubMed 18799455]).[supplied by OMIM, Jun 2009]
Gene Name: SUMO1/sentrin Specific Peptidase 6
Chromosome: CHR6: 76311621 -76427994
Locus: 6q14.1
Gene Diseases
The SENP6 GPR124 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|